PRESIDENT HAS SERVED AS A REVIEWER FOR THE BST-F (80) BIOENGINEERING ‘ACADEMIC RESEARCH ENHANCEMENT AWARD’ STUDY SECTION FOR THE NIH

PDX Pharma’s President has served as a reviewer for the BST-F (80) Bioengineering ‘Academic Research Enhancement Award’ Study Section for the National Institute of Health (NIH) held on September 14, 2017.

pdx news

  • PDX Pharmaceuticals Secures Additional Investment from the Kuni Foundation to Advance New Cancer-Fighting Precision Therapies

    2/9/2021
    read more

  • PDX Pharmaceuticals filed international patent applications (PCT) on cancer immunotherapeutics and a provisional application on COVID-19 vaccine

    7/17/2020
    read more

  • Augmenting the therapeutic window of radiotherapy: A perspective on molecularly targeted therapies and nanomaterials

    6/30/2020
    read more

Copyright © 2017 PDX Pharmaceuticals, Inc. All rights reserved